• HCC-specific survival from start of treatment
• Time to response from start of treatment (complete or partial response)
• Proportion of patients who achieve partial/complete response
• Time to progression measured from start of treatment
• Duration of complete response in patients showing a complete response, measured from the first date when absence of disease was recorded until the first date of disease progression was recorded
• Duration of partial response in patients showing partial response, measured from first date when partial response was recorded until the first date at which disease progression was observed
• Duration of stable disease measured from start of treatment until the first date where either progression or partial/complete response was observed
• Change(s) in tumour size
• Change in tumour marker
• Number of days of hospitalisation (in-patient care)
• Quality of life
• Adverse events
• Change in laboratory values
• Dose of seocalcitol (seocalcitol treated patients)

• HCC-specific survival from start of treatment.
• Time to response from start of treatment (complete or partial response).
• Proportion of patients who achieve partial/complete response
• Time to progression measured from start of treatment.
• Duration of complete response in patients showing a complete response, measured from the first date when absence of disease was recorded until the first date of disease progression was recorded.
• Duration of partial response in patients showing partial response, measured from first date when partial response was recorded until the first date at which disease progression was observed.
• Duration of stable disease measured from start of treatment until the first date where either progression or partial/complete response was observed.
• Change(s) in tumour size.
• Change in tumour marker.
• No. of days of hospitalisation (in-patient care).
• Quality of life.
• Adverse events.
• Change in laboratory values.
• Dose of Seocalcitol (Seocalcitol treated patients).

The purpose of the study is to determine whether seocalcitol is effective in the treatment of advanced primary liver cancer (hepatocellular carcinoma [HCC]).

Inclusion Criteria:

• Hospital in- or out-patients
• Either sex
• Aged 18-75 years
• With hepatocellular carcinoma, verified by histology/cytology, which is not amenable to curative treatment or transplantation.
• Patients must have measurable disease, and be classifiable as to Barcelona Clinic Liver Cancer (BCLC) stage 0, as described in Llovet JM et al. Hepatology 1999;29:62-67.

Exclusion Criteria:

• Patients treated with chemotherapy or other anti-cancer therapy within 4 weeks before visit 1
• Patients with another primary tumor, except for basocellular carcinoma of the skin or in situ carcinoma of the cervix, within the last 2 years
• A history of renal stone(s)
• A life expectancy of < 3 months
• World Health Organization (WHO) performance status 3 or 4
• Okuda stage III.
• Patients with hypercalcemia, or other clinically important laboratory abnormalities
• Patients with previous/current calcium metabolic disease, taking calcium-lowering therapy, or medication known to affect systemic calcium metabolism are also excluded.
• All patients must give their signed informed consent to join the study.